Advances in Biomarkers in Chronic Obstructive Pulmonary
Disease Combined with Lung Cancer

Jun Gao; Cuifang Li; Jiayin Zhou; Yaqing Wang; Jinrong Wang*

doi:10.70711/mhr.v2i5.6287

Advances in Biomarkers in Chronic Obstructive Pulmonary Disease Combined with Lung Cancer

Jun Gao, Cuifang Li, Jiayin Zhou, Yaqing Wang, Jinrong Wang*

Abstract

Chronic obstructive pulmonary disease (COPD) and lung cancer(LC) are the two major diseases that contribute to the global burden of respiratory disease, and they influence each other. The presence of COPD increases the risk of LC, and LC is the leading cause of death
in patients with COPD. The clinical features of COPD and LC are not highly specific, so the diagnosis of COPD-LC is predominantly made
at a late stage. By applying biomarkers to detect patients with COPD-LC, early diagnosis and timely intervention can be achieved, and the
prognosis of patients can be improved. In this paper, inflammation-related markers (IL-6, IL-8, IL-17, IL-33, etc.), epigenetic-related markers
(miR-206, miR-1246, etc.), immune-related markers (CCL18, CCL21, CX3CL1, etc.), coagulation-related markers (D-D, FIB), tumor-related
markers (CEA, CA125, NSE) and other biomarkers were reviewed, which can provide clues for early screening and diagnosis of COPD-LC.

Keywords

Chronic obstructive pulmonary disease; Lung cancer; Biomarkers

Full Text:

PDF

Included Database

References

[1] Zhou C, Qin Y, Zhao W, et al. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease [J]. Transl Lung Cancer Res, 2023, 12(8): 1661-1701.

[2] Agust A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary [J].

Eur Respir J, 2023, 61(4).

[3] Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention [J]. Clin Chest Med, 2020, 41(1): 1-24.

[4] Huseb GR, Nielsen R, Hardie J, et al. Risk factors for lung cancer in COPD - results from the Bergen COPD cohort study [J]. Respir

Med, 2019, 152: 81-88.

[5] Ma H, Zhang Q, Zhao Y, et al. Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive

Pulmonary Disease ( COPD) [J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 1601-1612.

[6] Machida H, Inoue S, Shibata Y, et al. The Incidence and Risk Analysis of Lung Cancer Development in Patients with Chronic Obstructive Pulmonary Disease: Possible Effectiveness of Annual CT-Screening [J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 739-749.

[7] Forder A, Zhuang R, Souza VGP, et al. Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer [J]. Int J Mol Sci,

2023, 24(3).

[8] Li X, Li J, Zhang Y, et al. [The role of IL-8 in the chronic airway inflammation and its research progress] [J]. Lin Chuang Er Bi Yan

Hou Tou Jing Wai Ke Za Zhi, 2021, 35(12): 1144-1148.

[9] Dawson RE, Jenkins BJ, Saad MI. IL-6 family cytokines in respiratory health and disease [J]. Cytokine, 2021, 143: 155520.

[10] Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers [J]. Front Oncol, 2022, 12: 1023177.

[11] Li CH, Yang YC, Hsia TC, et al. Association of Interleukin-8 Promoter Genotypes With Taiwan Lung Cancer Risk [J]. Anticancer Res,

2022, 42(3): 1229-1236.

[12] Mouronte-Roibs C, Leiro-Fernndez V, Ruano-Ravia A, et al. Predictive value of a series of inflammatory markers in COPD for lung

cancer diagnosis: a case-control study [J]. Respir Res, 2019, 20(1): 198.

[13] Yang T. Expression Profile of IL-17 in Lung Tissues of Patients with Lung Cancer and COPD and Clinical Significance [J]. Cell Mol

Biol (Noisy-le-grand), 2022, 68(9): 135-139.

[14] Strickson S, Houslay KF, Negri VA, et al. Oxidized IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex [J]. Eur Respir J, 2023, 62(3).

[15] Yang K, Tian C, Zhang C, et al. The Controversial Role of IL-33 in Lung Cancer [J]. Front Immunol, 2022, 13: 897356.

[16] Erciyestepe M, Selvi O, Din Sonu?en ?, et al. Prognostic Value of ?nflammation And Nutrition-Based Scores in Non-Small Cell Lung

Cancer [J]. Med Princ Pract, 2023.

[17] Xu F, Xu P, Cui W, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell

lung cancer and predicting Tumor-Node-Metastasis stages [J]. Oncol Lett, 2018, 16(1): 483-490.

[18] Chen GQ. Study on the correlation between NLR, PLR and urinary OPN protein and COPD combined with lung cancer based on the lung

tonic water channel [D]: Xinjiang Medical University, 2023.

[19] Qi C, Sun SW, Xiong XZ. From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis [J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 2603-2621.

[20] Lai X, Zhong J, Zhang B, et al. Exosomal Non-Coding RNAs: Novel Regulators of Macrophage-Linked Intercellular Communication in

Lung Cancer and Inflammatory Lung Diseases [J]. Biomolecules, 2023, 13(3).

[21] Cern-Pisa N, Iglesias A, Shafiek H, et al. Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as Potential Specific miRNA Biomarkers of COPD: A Pilot Study [J]. Pathophysiology, 2022, 29(2): 143-156.

[22] Lobera ES, Varela MA, Jimenez RL, et al. miRNA as biomarker in lung cancer [J]. Mol Biol Rep, 2023, 50(11): 9521-9527.

[23] Bahari Khasraghi L, Nouri M, Vazirzadeh M, et al. MicroRNA-206 in human cancer: mechanistic and clinical perspectives [J]. Cell Signal, 2023, 101: 110525.

[24] Aiso T, Ueda M. 5-isomiR is the most abundant sequence of miR-1246, a candidate biomarker of lung cancer, in serum [J]. Mol Med

Rep, 2023, 27(4).

[25] Crdoba-Lans E, Domnguez de-Barros A, Oliva A, et al. Circulating miR-206 and miR-1246 as Markers in the Early Diagnosis of

Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease [J]. Int J Mol Sci, 2023, 24(15).

[26] Devadoss D, Long C, Langley RJ, et al. Long Noncoding Transcriptome in Chronic Obstructive Pulmonary Disease [J]. Am J Respir

Cell Mol Biol, 2019, 61(6): 678-688.

[27] Song B, Ye L, Wu S, et al. Long non-coding RNA MEG3 regulates CSE-induced apoptosis and inflammation via regulating miR-218 in

16HBE cells [J]. Biochem Biophys Res Commun, 2020, 521(2): 368-374.

[28] Li H, Wang J, Lv S, et al. Long noncoding RNA MEG3 plays a promoting role in the proliferation, invasion, and angiogenesis of lung

adenocarcinoma cells through the AKT pathway [J]. J Cell Biochem, 2019, 120(9): 16143-16152.

[29] Qin K, Xu B, Pang M, et al. The functions of CD4 T-helper lymphocytes in chronic obstructive pulmonary disease [J]. Acta Biochim

Biophys Sin (Shanghai), 2022, 54(2): 173-178.

[30] Mateu-Jimenez M, Curull V, Pijuan L, et al. Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer:

Influence of Underlying Chronic Respiratory Disease [J]. J Thorac Oncol, 2017, 12(2): 235-248.

[31] Thomas R, Qiao S, Yang X. Th17/Treg Imbalance: Implications in Lung Inflammatory Diseases [J]. Int J Mol Sci, 2023, 24(5).

[32] Zhou J, Wang W, Liu R. [Research Progress of Treg/Th17 in the Treatment of Chronic Obstructive Pulmonary Disease with Lung Cancer] [J]. Zhongguo Fei Ai Za Zhi, 2019, 22(12): 794-797.

[33] Sha Zhenkai, Li Linjing, Zhang Xiangjie, et al. Relationship between helper T-cell levels and disease occurrence in patients with chronic

obstructive pulmonary disease combined with lung cancer [J]. Journal of Clinical Pulmonology, 2020, 25(07): 977-982.

[34] Xu QH, Huang SP, Li WL, et al. Expression of CCL-18 and CX3CL1 in Serum, and Their Potential Roles as Two Diagnostic and Prognostic Markers in Chronic Obstructive Pulmonary Disease and Chronic cor Pulmonale (COPD&CCP): a Pilot Study [J]. Clin Lab, 2020,

66(10).

[35] Luo HQ, Huang YM, Li J, et al. DHA inhibits invasion and metastasis in NSCLC cells by interfering with CCL18/STAT3 signaling

pathway [J]. Clin Exp Med, 2023, 23(6): 2311-2320.

[36] Fan M, Wu J, Li X, et al. CX(3) CL1 promotes tumour cell by inducing tyrosine phosphorylation of cortactin in lung cancer [J]. J Cell

Mol Med, 2021, 25(1): 132-146.

[37] Ku?nar-Kami?ska B, Miku?a-Pietrasik J, Sosi?ska P, et al. COPD promotes migration of A549 lung cancer cells: the role of chemokine

CCL21 [J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 1061-1066.

[38] Zhang X, Liu J, Ma HX. Correlation between serum chemokine CCL18 and CCL21 levels and lung cancer in chronic obstructive pulmonary disease [J]. Journal of Clinical Pulmonology, 2021, 26(07): 1004-1007.

[39] Liu M, Hu R, Jiang X, et al. Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia [J]. J Clin

Lab Anal, 2021, 35(4): e23733.

[40] Chen C, Li J, Li J, et al. Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small

cell lung cancer [J]. Ann Transl Med, 2020, 8(18): 1153.

[41] Chen L, Xu W, Chen J, et al. Evaluating the clinical role of fibrinogen, D-dimer, mean platelet volume in patients with acute exacerbation of COPD [J]. Heart Lung, 2023, 57: 54-58.

[42] Ma M, Cao R, Wang W, et al. The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and metaanalysis [J]. J Cardiothorac Surg, 2021, 16(1): 243.

[43] Song X, Wang F, Shen H, et al. [Correlation between Plasma D-dimer Count and Features of Non-small Cell Lung Cancer] [J]. Zhongguo Fei Ai Za Zhi, 2019, 22(3): 151-156.

[44] Zhang JJ. Exploring the correlation between combined serum CA125, NSE, and CEA with COPD combined with lung cancer and Chinese medicine evidence [D]: Xinjiang Medical University, 2023.

[45] Hu X, Xu J, Li P, et al. Correlation of Serum Clara Cell Secretory Protein 16, Plasma Fibrinogen and Serum Amyloid A with the Severity of Acute Exacerbated COPD and Their Combination in Prognosis Assessment [J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 1949-

1957.

[46] Li SQ, Jiang YH, Lin J, et al. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung

cancer individuals [J]. Cancer Med, 2018, 7(4): 1221-1231.

[47] Barouchos N, Papazafiropoulou A, Iacovidou N, et al. Comparison of tumor markers and inflammatory biomarkers in chronic obstruc-

tive pulmonary disease (COPD) exacerbations [J]. Scand J Clin Lab Invest, 2015, 75(2): 126-132.

[48] Bi H, Yin L, Fang W, et al. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics

and Chemotherapeutic Outcomes of Lung Cancer [J]. Lab Med, 2023, 54(4): 372-379.

[49] Jia Q, Ouyang Y, Yang Y, et al. Osteopontin: A Novel Therapeutic Target for Respiratory Diseases [J]. Lung, 2024, 202(1): 25-39.

[50] Mou S, Zhang W, Deng Y, et al. Comparison of CRP, Procalcitonin, Neutrophil Counts, Eosinophil Counts, sTREM-1, and OPN between Pneumonic and Nonpneumonic Exacerbations in COPD Patients [J]. Can Respir J, 2022, 2022: 7609083.

[51] Hao C, Cui Y, Chang S, et al. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON

tyrosine kinase [J]. Sci Rep, 2019, 9(1): 18101.

[52] Petta V, Loukides S, Kostikas K, et al. Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does

the co existence make the difference?[J]. J Thorac Dis, 2018, 10(2): 740-748.

[53] Arrey Agbor DB, Kari M, Chukka RCH, et al. Prevalence and Impact of Thyroid Dysfunction in Patients With Chronic Pulmonary Obstructive Pulmonary Disorder: a Systematic Review and Meta-Analysis [J]. Cureus, 2024, 16(2): e54968.

[54] Huang D, Wu D, He J, et al. Association Between Thyroid Function and Acute Exacerbation of Chronic Obstructive Pulmonary Disease

[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 333-339.

[55] Ma Z, Song P, Ji D, et al. Thyroid hormones as biomarkers of lung cancer: a retrospective study [J]. Ann Med, 2023, 55(1): 2196088.

DOI: http://dx.doi.org/10.70711/mhr.v2i5.6287

Refbacks

There are currently no refbacks.